CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions.
Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞疗法已在血液系统恶性肿瘤中展现出显著的临床疗效。CAR-T 细胞疗法的最新进展已将其应用扩展至其他人群,包括老年患者以及中枢神经系统肿瘤和实体瘤患者。尽管其对某些恶性肿瘤的临床疗效优异,但CAR-T 细胞疗法与严重甚至危及生命的免疫介导毒性相关,包括细胞因子释放综合征和神经毒性。大量科学证据强调免疫激活与神经认知和心理现象之间的联系。迄今为止,在免疫治疗背景下对这一关系的研究仍然有限。在本综述中,我们提出一个生物行为学框架,以指导当前和未来的细胞治疗研究,并有助于改善接受CAR-T 细胞治疗患者的多维度结局。
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable clinical responses in hematologic malignancies. Recent advances in CAR T-cell therapy have expanded its application into other populations including older patients and those with central nervous system and solid tumors. Although its clinical efficacy has been excellent for some malignancies, CAR T-cell therapy is associated with severe and even life-threatening immune-mediated toxicities, including cytokine release syndrome and neurotoxicity.
There is a strong body of scientific evidence highlighting the connection between immune activation and neurocognitive and psychological phenomena. To date, there has been limited investigation into this relationship in the context of immunotherapy. In this review, we present a biobehavioral framework to inform current and future cellular therapy research and contribute to improving the multidimensional outcomes of patients receiving CAR T-cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。